Pfizer biotech spinout nabs $125M megaround as Bain-backed syndicate bets on its late-stage game plan
SpringWorks Therapeutics launched in the fall of 2017 with a whopping $103 million round and some well-developed Pfizer assets that the company had high …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
